Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi AppTec Reports 2023 Results; US Biopharmas Are 65% of Its Business

publication date: Mar 19, 2024

WuXi AppTec, the China-based CRDMO, reported 2023 results showing a modest gain in revenue (2.5%) to over 40 billion RMB ($5.6 billion) for the year earlier, an increase that is significantly higher if the 2022 COVID revenues are subtracted – then the increase climbs to 25.6%. WuXi now provides services to 6000 companies. But there is a very sour note to this success: 65% of WuXi’s business is with US-based companies, which means that pending legislation in Congress, aimed at shutting down WuXi’s US business, could reduce WuXi’s income by $3.6 billion. More details....

Stock Symbols: (SHA: 603259/HK: 2359)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital